Premium
Overexpression of complement receptors and related antigens on the surface of bone marrow mast cells in patients with systemic mastocytosis
Author(s) -
NúñezLópez Rosa,
Escribano Luis,
Schernthaner GeritHolger,
Prados Aránzazu,
RodríguezGonzález Ramón,
DíazAgustín Beatriz,
López Antonio,
Hauswirth Alexander,
Valent Peter,
Almeida Julia,
Bravo Pilar,
Orfao Alberto
Publication year - 2003
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2003.04055.x
Subject(s) - cd59 , complement receptor 1 , complement system , systemic mastocytosis , bone marrow , immunology , antigen , complement receptor , mast cell , cd11c , receptor , flow cytometry , decay accelerating factor , biology , medicine , immune system , biochemistry , phenotype , gene
Summary. Depending on their stage of maturation and other factors, mast cell (MC) subsets differ from each other in terms of the expression of complement‐associated antigens. This study analysed the expression of various complement‐related cell surface antigens (CD11b/CR3, CD11c/CR4, CD35/CR1, CD55/DAF, CD59/MIRL, CD88/C5aR) on bone marrow mast cells (BMMC) in patients suffering from systemic mastocytosis (SM), other haematological diseases and non‐haematological disorders (control groups). Expression of complement‐associated cell surface antigens was analysed by flow cytometry. There were clear immunophenotypic differences between BMMC obtained from patients with SM and those from the control subjects: the percentage of patients expressing surface CD11c, CD35 and CD88 was significantly higher in patients with SM (76%, 100%, 54%) than in the control subjects (58%, 11%, 18%) ( P < 0·05). In addition, the levels of CD11c, CD35 and CD88 expressed per MC (sites per cell) were significantly higher ( P < 0·05) in SM than in the control group. Expression of the complement regulatory molecules CD55 and CD59 was detected in BMMC in all patients analysed. However, the levels of CD59 per BMMC were higher in patients with SM as compared with the control subjects, which could help to explain the formation of BMMC aggregates in the former group of individuals. Together, our results showed that BMMC in systemic mastocytosis overexpressed the cell surface membrane receptors involved in binding of complement components and complement‐mediated cell activation. Whether this pathological expression of complement receptors is of pathophysiological significance remains to be determined.